What Is Oral Semaglutide and How Does It Compare to Injections?

Why is the tablet dose so much bigger than the injection dose?

The tablet's maintenance dose is 25 mg once daily, while a common injection maintenance dose is 2.4 mg once weekly — the two milligram numbers don't translate across forms. For weight reduction in adults, the Wegovy injection maintenance dose is 1.7 mg or 2.4 mg once weekly, and may be increased to a maximum of 7.2 mg once weekly if further weight reduction is needed and the dose is tolerated. So, per the Wegovy prescribing information as of August 2026, a maintenance tablet is 25 mg every day, and a common maintenance injection is 2.4 mg once a week. We do not have a source for the absorption pharmacology behind that gap, so we do not explain it.

Milligram numbers do not translate across forms, or across oral brands. A second dosage form, OZEMPIC (oral semaglutide) tablet, shares a DailyMed label with RYBELSUS (oral semaglutide) tablet, but OZEMPIC tablet strengths (1.5 mg, 4 mg, 9 mg) differ from the RYBELSUS strengths (3 mg, 7 mg, 14 mg), so the two brands are not interchangeable milligram-for-milligram. OZEMPIC tablets also treat something different: they are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus — see Ozempic vs. Wegovy for the full comparison.

What did the OASIS 4 and STEP 1 trials show?

In the OASIS 4 trial, per the publication as of August 2026, mean change in body weight at week 64 was -13.6% with oral semaglutide 25 mg once daily versus -2.2% with placebo (estimated difference -11.4 percentage points), in a 71-week trial of 307 adults (205 semaglutide, 102 placebo). In the STEP 1 trial, per the publication as of August 2026, mean change in body weight from baseline to week 68 was -14.9% with once-weekly subcutaneous semaglutide 2.4 mg versus -2.4% with placebo, in 1,961 adults with overweight or obesity without diabetes.

These are two separate trials, run at different sizes, over different lengths, with differently defined populations, per the trial publications as of August 2026. OASIS 4 enrolled adults without diabetes who had a body-mass index of 30 or higher, or a BMI of 27 or higher with at least one obesity-related complication. Neither was designed to test the tablet against the injection; we have no head-to-head trial to cite. Per the OASIS 4 and STEP 1 publications, treat -13.6% and -14.9% as two facts, not a ranking, and do not read the 1.3-point gap as a measured difference between forms.

One thing the tablet trial does settle: the pill is not a way around stomach side effects. In OASIS 4, per the publication as of August 2026, gastrointestinal adverse events were more common with oral semaglutide 25 mg than with placebo (74.0% versus 42.2%).

Do I need to take the Wegovy tablet on an empty stomach?

Yes — the tablet rule, quoted in full in the table above, is an empty stomach in the morning, up to 4 ounces of water, then at least 30 minutes before food, other beverages, or other oral medications. Wegovy tablets must be swallowed whole and must not be split, crushed, chewed, or dissolved. The injection, by contrast, is once weekly, with or without meals.

That is 365 mornings of protocol against 52 injections with no food rule. If you take other medications on waking, the 30-minute window has to be built around them; we have no published data on real-world adherence to it.

Who might choose the tablet, and who might choose the injection?

It depends on what matters most to you — needles, morning routines, age, or specific health conditions.

• Needles the barrier: the tablet's adult weight indication is written in the same terms as the injection's.
• Unpredictable mornings, or other oral medications on waking: the 30-minute empty-stomach rule is a daily constraint.
• Under 18: only the injection carries the pediatric (12 and older) weight-reduction indication.
• Noncirrhotic MASH (F2-F3): the indication does not apply to Wegovy tablets.
• Cardiovascular risk reduction: both forms carry that indication (see table).
• Already on a GLP-1: concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

How much does oral semaglutide cost, and will insurance cover it?

Prices below are promotional and change on the dates noted; verified August 24, 2026.

Novo Nordisk's list price is $1,349.02 per package, but self-pay tiers start at $149/month and eligible Medicare beneficiaries can pay $50/month through the GLP-1 Bridge — actual plan coverage varies. As of August 2026, Novo Nordisk states a list price of $1,349.02 per package for the Wegovy pill, the Wegovy pen, and the Wegovy HD pen; list price is the manufacturer price before discounts or rebates, and most insured patients pay less. Under the Medicare GLP-1 Bridge program (July 1, 2026 through December 31, 2027), all dose strengths of the Wegovy pen and pill are $50 per month — but only for beneficiaries who meet the program's own eligibility rules (a qualifying Medicare Part D plan, a qualifying BMI, and no type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease), not every Part D enrollee. Separately, CMS negotiated a Medicare maximum fair price of $274 for a 30-day supply of the selected drug Ozempic; Rybelsus; Wegovy (Novo Nordisk Inc.), taking effect January 1, 2027.

As of August 2026, Measured lists Wegovy, Ozempic, Zepbound, and the Wegovy Pill at a membership price starting from $49/mo. Measured lists the Wegovy Pill (daily oral semaglutide) as "No insurance required" and Wegovy as available "With and without insurance," with medication paid separately from membership in both cases. As of August 2026, Measured lists Compounded Semaglutide as "No insurance required" with medication included in the membership price, from $119/mo. Compounded medications are not reviewed or approved by the FDA for safety or effectiveness.

Whether any specific plan covers either form is a question about that plan's formulary and rules. Measured states that many insurance plans require a prior authorization before they will cover brand-name GLP-1s such as Ozempic, Wegovy, Mounjaro, or Zepbound. Preauthorization is not a promise that the health insurance plan will cover the cost of the service or drug. If a prior authorization is approved, Measured states the patient pays only their plan's copay at the pharmacy; as of August 2026, Measured states many patients have GLP-1 copays around $20, though actual out-of-pocket cost depends on the specific plan and pharmacy benefits.

Delivery differs by pathway: insurance-covered GLP-1s go to the patient's pharmacy of choice; cash-pay GLP-1s, compounded GLP-1s, and oral medications ship directly to the patient's home free of charge.

Can I switch between the Wegovy tablet and the injection?

Yes, following the label's specific crossover points, not just separate ladders. Patients taking the 2.4 mg injection for weight reduction or cardiovascular risk reduction may switch to the 25 mg tablet, starting it one week after the last injection dose. Going the other direction, a patient may switch from the 25 mg tablet to the injection, starting 2.4 mg subcutaneously the day after the last tablet dose; if the 25 mg tablet was not tolerated, the label calls for the 1.7 mg injection instead. Outside those two specific crossover points, a switch is a prescriber decision about where you restart and how fast you titrate.

What are the side effects and safety warnings for the Wegovy tablet and injection?

Wegovy carries a boxed warning for risk of thyroid C-cell tumors: in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy is contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy injection or Wegovy tablets.

Per the Wegovy label as of August 2026, the most common adverse reactions (incidence at or above 5%) in adults or pediatric patients aged 12 years and older are nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss. Acute pancreatitis has occurred in clinical trials with semaglutide; Wegovy should be discontinued promptly if pancreatitis is suspected and should not be restarted if pancreatitis is confirmed.

This page is general information, not medical advice; bring it to your prescriber.